Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Matinas BioPharma Holdings, Inc.
  6. Summary
    MTNB   US5768101058

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
Delayed Nyse  -  05/16 04:00:00 pm EDT
0.6600 USD   -1.58%
05/12TRANSCRIPT : Matinas BioPharma Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12MATINAS BIOPHARMA HOLDINGS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
0.6523(c) 0.6282(c) 0.6408(c) 0.6706(c) 0.66(c) Last
600 148 510 368 337 956 810 858 152 250 Volume
+3.54% -3.69% +2.01% +4.65% -1.58% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,01 M - -
Net income 2022 -28,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,03x
Yield 2022 -
Sales 2023 0,01 M - -
Net income 2023 -32,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -4,79x
Yield 2023 -
Capitalization 145 M 145 M -
Capi. / Sales 2022 18 179x
Capi. / Sales 2023 19 135x
Nbr of Employees 31
Free-Float 97,1%
More Financials
Company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on redefining the intracellular delivery of nucleic acids and small molecules through its lipid nanocrystal (LNC) drug delivery platform. The Company is engaged in developing LYPDISO, as well as its LNC platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501. Its LNC platform is... 
Read more
More about the company
Ratings of Matinas BioPharma Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D-
More Ratings
All news about MATINAS BIOPHARMA HOLDINGS, INC.
05/12TRANSCRIPT : Matinas BioPharma Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12MATINAS BIOPHARMA HOLDINGS, INC. : Results of Operations and Financial Condition, Regulati..
AQ
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highligh..
GL
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highligh..
GL
05/12Note 2 - Liquidity and Plan of Operations
AQ
05/12Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended M..
CI
05/05Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial an..
GL
05/03Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
GL
05/03Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
AQ
04/13MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure (form 8-K)
AQ
04/11SECTOR UPDATE : Health Care
MT
04/11SECTOR UPDATE : Health Care Stocks Decline Premarket Monday
MT
04/11BioNTech, Matinas BioPharma Sign Exclusive Research Deal on Lipid Nanocrystal Technolog..
MT
04/11MATINAS BIOPHARMA : BioNTech and Matinas BioPharma Announce Exclusive Research Collaborati..
PU
04/11MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
More news
News in other languages on MATINAS BIOPHARMA HOLDINGS, INC.
05/12Matinas BioPharma Holdings, Inc. annonce ses résultats pour le premier trimestre clos l..
04/11MISE À JOUR SECTORIELLE : Soins de santé
04/11MISE À JOUR SECTORIELLE : Les actions du secteur de la santé chutent lundi avant le marché
04/11BioNTech et Matinas BioPharma signent un accord de recherche exclusif sur la technologi..
04/11BioNTech et Matinas BioPharma annoncent une collaboration de recherche exclusive pour é..
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,67 $
Average target price 2,75 $
Spread / Average Target 310%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-33.60%145
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153